首页> 外文期刊>American Journal of Clinical Oncology: Cancer Clinical Trials >Basics of particle therapy II biologic and dosimetric aspects of clinical hadron therapy.
【24h】

Basics of particle therapy II biologic and dosimetric aspects of clinical hadron therapy.

机译:粒子疗法的基础II临床强子疗法的生物学和剂量学方面。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Besides photons and electrons, high-energy particles like protons, neutrons, He ions or heavier ions (C, Ne, etc) have been finding increasing applications in the treatment of radioresistant tumors and tumors located near critical structures. The main difference between photons and hadrons is their different biologic effect and depth-dose distribution. Generally speaking, protons are superior in dosimetric aspects whereas neutrons have advantages in biologic effectiveness because of the high linear energy transfer. In 1946 Robert Wilson first published the physical advantages in dose distribution of ion particles for cancer therapy. Since that time hadronic radiotherapy has been intensively studied in physics laboratories worldwide and clinical application have gradually come to fruition. Hadron therapy was made possible by the advances in accelerator technology, which increases the particles' energy high enough to place them at any depth within the patient's body. As a follow-up to the previous article Introduction to Hadrons, this review discusses certain biologic and dosimetric aspects of using protons, neutrons, and heavy charged particles for radiation therapy.
机译:除光子和电子外,高能粒子如质子,中子,He离子或重离子(C,Ne等)已在治疗抗辐射肿瘤和关键结构附近的肿瘤中得到越来越多的应用。光子和强子之间的主要区别是它们的生物效应和深度剂量分布不同。一般而言,质子在剂量学方面优越,而中子由于高的线性能量传递而在生物有效性方面具有优势。 1946年,罗伯特·威尔逊(Robert Wilson)首次发表了用于癌症治疗的离子颗粒剂量分布的物理优势。从那时起,全世界的物理实验室都对强子放射疗法进行了深入研究,临床应用也逐渐取得了成果。加速器技术的进步使强子疗法成为可能,加速器技术将粒子的能量提高到足以将其放置在患者体内任何深度的高度。作为上一篇文章《强子论简介》的后续,本篇文章讨论了使用质子,中子和重荷粒子进行放射治疗的某些生物学和剂量学方面。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号